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Abstract
Background: Metabolic syndrome (MetS) is associated with an increased risk of major cardiovascular events.
Increased high-sensitivity C-reactive protein (hsCRP) levels are associated with MetS and its components. Changes
in gamma-glutamyl transferase (GGT) levels in response to oxidative stress are also associated with MetS, and the
levels could be modulated by hsCRP.
Methods: From a single community, we recruited 822 men (mean age, 61 ± 14 years) and 1,097 women (63 ± 12
years) during their annual health examination. We investigated whether increased hsCRP and GGT levels are
synergistically associated with MetS and insulin resistance evaluated by Homeostasis of model assessment of
insulin resistance (HOMA-IR).
Results: Of these subjects, 141 men (17.2%) and 170 women (15.5%) had MetS. Participants with MetS had a
higher hsCRP and GGT level than those without MetS in both genders, and the HOMA-IR increased significantly in
correlation with an increase in hsCRP and GGT. In men, the adjusted odds ratios (95% confidence interval) for MetS
across tertiles of hsCRP and GGT were 1.00, 1.69 (1.01-2.80), and 2.13 (1.29-3.52), and 1.00, 3.26 (1.84-5.78) and 6.11
(3.30-11.3), respectively. In women, the respective corresponding values were 1.00, 1.54 (0.92-2.60), and 3.08 (1.88-
5.06), and 1.00, 1.70 (1.04-2.79) and 2.67 (1.66-4.30). The interaction between increased hsCRP and GGT was a
significant and independent determinant for MetS and insulin resistance in both genders.
Conclusions: These results suggested that higher CRP and GGT levels were synergistically associated with MetS
and insulin resistance, independently of other confounding factor in the general population.
Introduction
Metabolic syndrome (MetS), a clustering of cardiovascu-
lar risk factors such as insulin resistance, hypertension,
glucose intolerance, hypertriglyceridemia, and low high-
density lipoprotein cholesterol (HDL-C) levels, is a
major worldwide public health problem. MetS increases
the risk of atherosclerotic disease, diabetes [1,2], and
cardiovascular disease (CVD) [3]. MetS affects 13.3% to
24.4% of Japanese men ≥ 30 years of age [4,5]. With the
continuous increase in obesity prevalence in Japan,
MetS may become even more common.
Recent data support the concept that high-sensitivity
C-reactive protein (hsCRP) is an inflammatory marker
and independent predictor reflecting the early stage of
CVD [6]. Several studies have demonstrated that hsCRP
is induced by cytokines produced by accumulated adipo-
cytes, and then increases in subjects with MetS [7,8].
Serum Gamma-Glutamyl Transferase is an enzyme
present on cell surfaces and in serum that contributes
to the extracellular catabolism of glutathione (GSH), but
most serum GGT is derived from the liver [9]. Gamma-
Glutamyl Transferase (GGT) is also a clinical marker of
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[10], plasma lipid/lipoproteins [11,12] and glucose levels
[12-14], blood pressure [12,14], and metabolic syndrome
[14,15]. It is also associated with CVD [14,15] and CVD
mortality [14-16]. In addition, Taki et al. [17] reported
that GGT showed a significant correlation with hsCRP,
suggesting a possible interaction between these two key
makers. However, there are few reports on the relation-
ship between CRP, GGT and MetS in Japan.
The aim of this study was to determine whether
increased hsCRP and GGT levels are interactively asso-
ciated with MetS, and we examined cross-sectional data
from Japanese community-dwelling participants.
Methods
Subjects
Participants were recruited at the time of their annual
health examination in a rural town located in Ehime pre-
fecture, Japan. Participants were recruited at the time of
their annual health examination in a rural town with a
total population of 11,136 (as of April 2002) and located
in Ehime prefecture, Japan, in 2002. Among the 9,133
adults (4,395 male) aged 19 to 90 years in this population,
a random sample of 3,164 (34.6%) subjects was recruited.
Other characteristics such as smoking and alcohol habits,
and medication, were investigated by individual inter-
views that were conducted using a structured question-
naire. The final study sample included 1,919 eligible
persons. All procedures were approved by the Ethics
Committee of Ehime University School of Medicine and
each subject gave informed consent to participate.
Evaluation of Risk Factors
Information on demographic characteristics and risk
factors was collected using the clinical files. Body mass
index was calculated by dividing weight (in kilograms)
by the square of the height (in meters). We measured
blood pressure with an appropriate-sized cuff on the
right upper arm of the subjects in a sedentary position
using an automatic oscillometric blood pressure recor-
der (BP-103i; Colin, Aichi, Japan) while they were seated
after having rested for at least 5 min. Smoking status
was defined as the number of cigarette packs per day
multiplied by the number of years smoked (pack year),
and the participants were classified into never smokers,
past smokers, light smokers (<30 pack year) and heavy
smokers (≥30 pack year). The daily alcohol consumption
was measured using the Japanese liquor unit in which a
unit corresponds to 22.9 g of ethanol, and the partici-
pants were classified into never drinkers, occasional
drinkers (<1 unit/day), light drinkers (1-1.9 unit/day),
and heavy drinkers (≥2 unit/day). Total cholesterol
(T-C), triglycerides (TG), HDL-C, fasting blood glucose
(FBG), creatinine (enzymatic method), uric acid,
immuno-reactive insulin (IRI), plasma high molecular
weight (HMW) adiponectin (FUJIREBIO, Tokyo, Japan),
hsCRP, and GGT were measured during fasting. Plasma
hsCRP concentration was measured using a Behring BN
II nephelometer (Dade Behring Inc., Marburg, Germany)
and this inter- and intraassay coefficient variations was
3.2 and 6.7%, respectively. Serum GGT concentration
was assayed with an automatic analyzer (TBA-c6000,
TOSHIBA, Tokyo) and this intraassay-coefficient of var-
iation was 0.87 to 2.11%. Low-density lipoprotein cho-
lesterol (LDL-C) level was calculated by the Friedewald
formula. Participants with TG levels ≥400 mg/dL were
excluded. Estimated GFR was calculated using the fol-
lowing equation: eGFR = 194×Cr
-1.094×Age
-0.287×0.739
(if female) [18]. Participants with an eGFR <30 mL/min/
1.73 m
2 were excluded. Homeostasis of model assess-
ment of insulin resistance (HOMA-IR) was calculated
from FBG and IRI levels using the following formula:
{FBG (mg/dL) × IRI (mU/mL)}/405 [19]. Insulin resis-
tance was defined as a HOMA-IR ≥2.6.
Metabolic Syndrome
We applied condition-specific cutoff points for MetS
based on the modified criteria of the National Choles-
terol Education Program’s Adult Treatment Panel
(NCEP-ATP) III report [20]. Metabolic syndrome was
defined as subjects with at least three or more of the
following five conditions: 1) obesity: BMI ≥25.0 kg/m
2
according to the guidelines of the Japanese Society for
the Study of Obesity (waist circumference was not avail-
able in this study) [21,22]; 2) raised BP with systolic
blood pressure (SBP) ≥130 mmHg and/or diastolic
blood pressure (DBP) ≥85 mmHg, and/or current treat-
ment for hypertension; 3) Hypertriglyceridemia with a
TG level ≥1.69 mmol/L (150 mg/dL); 4) low HDL cho-
lesterolemia with a HDL-C <1.04 mmol/L (40 mg/dL) in
men and 1.30 mmol/L (50 mg/dL) in women; and 5)
IFG with a FBG level ≥6.1 mmol/L (110 mg/dL) or cur-
rent treatment for diabetes mellitus.
Statistical Analysis
Data are presented as the mean ± standard deviation
(SD) unless otherwise specified, and in the cases of para-
meters with non-normal distributions (TG, IRI, FBG,
HOMA-IR, and GGT) the data are shown as median
(interquartile range) values. In all analyses, parameters
with non-normal distributions were used after log-trans-
formation. As several background differences between
men and women were demonstrated by previous studies
[2,16,22], statistical analysis was performed according to
sex using PASW Statistics 17.0 (Statistical Package for
Social Science Japan, Inc., Tokyo, Japan). The differences
among groups categorized by sex and presence of MetS
were analyzed by Student’s t-test for continuous
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2 -test for categorical variables. Corre-
lations between various characteristics and HOMA-IR
were determined using Pearson’s correlation. Subjects
were divided into three groups based on tertiles of
serum GGT and hsCRP within sex and then combined
to avoid the gender differences. Multiple logistic regres-
sion analysis was used to evaluate the contribution of
confounding factors for MetS and each component of
M e t S .T h es y n e r g i s t i ce f f e c to fC R Pa n dG G Tw a se v a l -
uated using a general linear model adjusted for the fol-
lowing parameters: age, smoking status, alcohol
consumption, uric acid, and estimated glomerular filtra-
tion rate. In addition, we demonstrated whether the
ORs for MetS and insulin resistance dose-dependently
increased in relation to hsCRP and GGT in subgroups
of confounding factors which effected on MetS and
insulin resistance (e.g., age, alcohol consumption, uric
acid, medication, HMW adiponectin). A p-value < 0.05
was considered significant.
Results
Characteristics of subjects
The characteristics of the study participants in relation to
sex are illustrated in Table 1. The study included 822
men, aged 61 ± 14 (range, 20-89) years, and 1,097
women, aged 63 ± 12 (range, 21-88) years. Smoking sta-
tus, alcohol consumption, history of CVD, DBP, TG, uric
acid, FBG, hsCRP, and GGT were higher in men than in
women, but age, HDL-C, LDL-C, presence of antilipi-
demic medication, IRI, HOMA-IR, and HMW adiponec-
tin were higher in women than in men. There was no
inter-group difference in BMI, SBP, presence of antihy-
pertensive medication, eGFR, and diabetic medication.
Association between various characteristics, and MetS
and insulin resistance
Table 2 shows the risk of MetS and abnormalities of its
components in relation to hsCRP and GGT among 822
m e na n d1 , 0 9 7w o m e n .O ft h e s e ,1 4 1m e n( 1 7 . 2 % )a n d
170 women (15.5%) had MetS. As shown Table 2, BMI,
S B P ,D B P ,T G ,L D L - C ,F B G ,H O M A - I R ,p r e s e n c eo f
diabetic medication, hsCRP, and GGT showed a higher
level in participants with MetS than those without in
both genders, but HDL-C and HMW adiponectin
showed a lower level in those with MetS. Age, presence
of antilipidemic medication, and uric acid were higher
only in women with MetS, but eGFR was lower in
women with MetS. In men, the HOMA-IR increased
significantly in correlation with an increase in BMI, SBP,
DBP, presence of antihypertensive medication, TG,
LDL-C, presence of antilipidemic medication, uric acid,
FBG, presence of diabetic medication, hsCRP, and GGT,
but decrease in age, HDL-C, and HMW adiponectin. In
women, the HOMA-IR increased significantly in
Table 1 Characteristics of subjects categorized according to sex
Characteristics Men (N = 822) Women (N = 1,097) P-value*
Age (years) 61 ± 14 63 ± 12 <0.001
Body mass index (kg/m
2) 23.6 ± 3.0 23.4 ± 3.4 0.154
Smoking status, % 41.6/24.8/14.6/19.0 97.5/0.8/1.5/0.1 <0.001
Alcohol consumption, % 14.6/28.5/34.3/22.6 64.6/30.0/4.9/0.5 <0.001
History of cardiovascular disease, % 9.9 6.8 0.011
Systolic blood pressure (mmHg) 140 ± 20 139 ± 23 0.064
Diastolic blood pressure (mmHg) 84 ± 11 80 ± 12 <0.001
Antihypertensive medication, % 24.7 25.6 0.343
Triglycerides (mmol/L) 1.08 (0.81-1.55) 1.01 (0.75-1.39) <0.001
HDL cholesterol (mmol/L) 1.53 ± 0.38 1.68 ± 0.40 <0.001
LDL cholesterol (mmol/L) 2.86 ± 0.81 3.26 ± 0.76 <0.001
Antilipidemic medication, % 3.9 6.7 0.005
Serum uric acid (μmol/L) 351 ± 83 265 ± 62 <0.001
eGFR (mL/min/1.73 m
2) 81.1 ± 17.0 80.2 ± 17.0 0.212
Immuno-reactive insulin (mU/mL) 4.7 (3.1-7.3) 6.0 (4.1-8.7) <0.001
Fasting blood glucose (mmol/L) 5.27 (4.94-5.77) 5.11 (4.83-5.55) <0.001
HOMA-IR 1.12 (0.70-1.86) 1.39 (0.91-2.08) <0.001
Diabetic medication, % 4.0 3.2 0.200
HMW adiponectin (μg/mL) 3.40 (2.01-5.34) 6.68 (4.39-9.65) <0.001
hsCRP (mg/L) 0.520 (0.280-1.073) 0.430 (0.220-0.870) <0.001
GGT (IU/L) 38 (25-68) 20 (16-28) <0.001
Data presented are mean ± standard deviation. HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate; HMW, high
molecular weight; hsCRP, high sensitivity C-reactive protein; GGT, gamma-glutamyl transferase. Data for triglycerides, fasting blood glucose, HOMA-IR, HMW
adiponectin, hsCRP, and GGT were skewed and are presented as median (interquartile range) values, and were log-transformed for analysis. *P-value from
Student’s t-test for continuous variables or from c
2-test for categorical variables.
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sence of antihypertensive medication, TG, LDL-C, pre-
sence of antilipidemic medication, uric acid, FBG,
presence of diabetic medication, hsCRP, and GGT, but
decrease in HDL-C, eGFR, and HMW adiponectin.
The adjusted odds ratio for MetS. its components, and
insulin resistance in relation to tertiles of hsCRP and GGT
As shown Table 3, after adjustments for age, smoking
status, alcohol consumption, uric acid, and eGFR, the
prevalence rate of MetS increased significantly in rela-
tion to hsCRP and GGT in both genders. In men, the
ORs (95% CI) for MetS across tertiles of hsCRP and
GGT were 1.00, 1.69 (1.01-2.80), and 2.13 (1.29-3.52),
and 1.00, 3.26 (1.84-5.78) and 6.11 (3.30-11.3), respec-
tively. In women, the ORs (95% CI) for MetS across ter-
tiles of hsCRP and GGT were 1.00, 1.54 (0.92-2.60), and
3.08 (1.88-5.06), and 1.00, 1.70 (1.04-2.79) and 2.67
(1.66-4.30), respectively. In men, the ORs of hsCRP
were significantly high for MetS components of obesity,
low HDL cholesterolemia, and impaired fasting glucose,
and the ORs of GGT were significantly high for obesity,
raised blood pressure, hypertriglyceridemia, and
impaired fasting glucose. In women, the ORs of hsCRP
were significantly high for MetS components of obesity,
hypertriglyceridemia, low HDL cholesterolemia, and
impaired fasting glucose, and the ORs of GGT were sig-
nificantly high for obesity, hypertriglyceridemia, and
Table 2 Association between various characteristics, and metabolic syndrome components and Insulin resistance
Metabolic syndrome HOMA-IR
Men, N = 822 Women, N = 1,097 Men, N = 822 Women,
N = 1,097
Pearson’s correlation
Characteristics No
N = 681
Yes
N = 141
P
-value*
No
N = 927
Yes
N = 170
P-
value*
r (P-value) r (P-value)
Age (years) 61 ± 14 60 ± 12 0.342 62 ± 12 66 ± 9 0.001 -0.141 (<0.001) 0.100 (0.001)
Body mass index (kg/m
2) 23.1 ± 2.8 26.1 ± 2.6 <0.001 22.8 ± 2.9 26.8 ± 3.6 <0.001 0.547 (<0.001) 0.516 (<0.001)
Smoking status, % 41.4/23.9/
15.7/18.9
42.6/29.1/9.2/
19.1
0.199 97.4/0.8/1.7/
0.1
98.2/1.2/0.6/0 0.636 -0.081 (0.020) 0.019 (0.536)
Alcohol consumption, % 14.4/28.0/
35.4/22.2
15.6/30.5/
29.1/24.8
0.555 63.3/30.9/5.4/
0.4
71.8/25.3/2.4/
0.6
0.120 -0.064 (0.066) -0.049 (0.104)
History of cardiovascular
disease, %
23.6 29.8 0.078 6.3 10.0 0.058 0.048 (0.171) 0.051 (0.090)
Systolic blood pressure
(mmHg)
139 ± 20 156 ± 17 0.001 136 ± 23 150 ± 20 <0.001 0.137 (<0.001) 0.245 (<0.001)
Diastolic blood pressure
(mmHg)
84 ± 11 88 ± 10 <0.001 79 ± 12 86 ± 10 <0.001 0.181 (<0.001) 0.230 (<0.001)
Antihypertensive
medication, %
23.6 29.8 0.078 21.1 50.0 <0.001 0.124 (<0.001) 0.195 (<0.001)
Triglycerides (mmol/L) 1.00 (0.77-
1.33)
1.89 (1.52-
2.60)
<0.001 0.94 (0.72-
1.23)
1.76 (1.21-
2.12)
<0.001 0.392 (<0.001) 0.365 (<0.001)
HDL cholesterol (mmol/L) 1.58 ± 0.37 1.27 ± 0.36 <0.001 1.74 ± 0.38 1.32 ± 0.32 <0.001 -0.319 (<0.001) -0.232 (<0.001)
LDL cholesterol (mmol/L) 2.83 ± 0.79 3.01 ± 0.92 0.019 3.24 ± 0.74 3.40 ± 0.85 0.011 0.206 (<0.001) 0.200 (<0.001)
Antilipidemic medication,
%
3.7 5.0 0.301 5.7 11.8 0.005 0.070 (0.044) 0.088 (0.004)
Serum uric acid (μmol/L) 349 ± 81 360 ± 91 0.146 261 ± 61 291 ± 58 <0.001 0.171 (<0.001) 0.252 (<0.001)
eGFR (mL/min/1.73 m
2) 80.9 ± 16.7 82.3 ± 18.6 0.385 80.9 ± 17.1 76.3 ± 16.2 0.001 -0.009 (0.791) -0.068 (0.024)
Fasting blood glucose
(mmol/L)
5.22 (4.94-
5.61)
6.11 (5.27-
6.83)
<0.001 5.05 (4.83-
5.44)
5.61 (5.11-
6.61)
<0.001 0.474 (<0.001) 0.540 (<0.001)
HOMA-IR 1.01 (0.65-
1.64)
2.21 (1.43-
3.20)
<0.001 1.27 (0.85-
1.79)
2.52 (1.80-
3.79)
<0.001 ———————— ————————
Diabetic medication, % 2.8 9.9 <0.001 2.2 8.8 <0.001 0.112 (0.001) 0.133 (<0.001)
HMW adiponectin (μg/
mL)
3.63 (2.18-
5.65)
2.28 (1.60-
3.69)
<0.001 7.09 (4.69-
10.3)
4.48 (3.12-
7.17)
<0.001 -0.331 (<0.001) -0.340 (<0.001)
hsCRP (mg/L) 0.480 (0.275-
1.015)
0.690 (0.400-
1.535)
<0.001 0.380 (0.200-
0.760)
0.750 (0.390-
1.613)
<0.001 0.163 (<0.001) 0.290 (<0.001)
GGT (IU/L) 35 (24-61) 55 (36-102) <0.001 20 (15-26) 25 (19-35) <0.001 0.240 (<0.001) 0.328 (<0.001)
Data presented are mean ± standard deviation. Metabolic syndrome was defined as having three or more of the following conditions: obesity, raised blood
pressure, hypertriglyceridemia, low HDL- cholesterolemia, and impaired fasting blood glucose. Data for triglycerides, fasting blood glucose, HOMA-IR, HMW
adiponectin, hsCRP, and GGT were skewed and are presented as median (interquartile range) values, and were log-transformed for analysis. *P-value from
Student’s t-test for continuous variables or from c
2-test for categorical variables.
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Men, N = 822 Women, N = 1,097
Tertile of hsCRP Tertile of GGT Tertile of hsCRP Tertile of GGT
1st 2nd 3rd 1st 2nd 3rd 1st 2nd 3rd 1st 2nd 3rd
Characteristics <0.360 0.360-0.800 >0.800 mg/L <29 29-54 >54 IU/L <0.280 0.280-0.650 >0.650 mg/L <18 18-24 >24 IU/L
Metabolic syndrome 29 (20.6%) 49 (34.8%) 63 (44.7%) 19 (13.5%) 51 (36.2%) 71 (50.4%) 25 (14.7%) 47 (27.6%) 98 (57.6%) 29 (17.1%) 54 (31.8%) 87 (51.2%)
OR (95% CI) 1.00 1.69 (1.01-
2.80)
2.13 (1.29-
3.52)
1.00 3.26 (1.84-
5.78)
6.11 (3.30-
11.3)
1.00 1.54 (0.92-
2.60)
3.08 (1.88-
5.06)
1.00 1.70 (1.04-
2.79)
2.67 (1.66-
4.30)
Obesity 61 (24.9%) 72 (29.4%) 112 (45.7%) 40 (16.3%) 88 (35.9%) 117 (47.8%) 49 (15.1%) 103 (31.7%) 173 (53.2%) 66 (20.3%) 107 (32.9%) 152 (46.8%)
OR (95% CI) 1.00 1.16 (0.76-
1.76)
2.21 (1.47-
3.32)
1.00 2.65 (1.71-
4.12)
4.75 (2.92-
7.72)
1.00 2.15 (1.46-
3.18)
4.04 (2.74-
5.97)
1.00 1.60 (1.11-
2.32)
2.17 (1.50-
3.12)
Raised blood pressure 186
(31.2%)
201 (33.7%) 209 (35.1%) 184
(30.9%)
208 (34.9%) 204 (34.2%) 220
(30.0%)
249 (34.0%) 264 (36.0%) 236
(32.2%)
245 (33.4%) 252 (34.4%)
OR (95% CI) 1.00 1.34 (0.88-
2.03)
1.20 (0.78-
1.85)
1.00 2.13 (1.38-
3.29)
2.72 (1.67-
4.43)
1.00 1.02 (0.71-
1.46)
0.97 (0.66-
1.42)
1.00 1.22 (0.85-
1.74)
1.19 (0.82-
1.73)
Hypertriglyceridemia 49 (27.7%) 62 (35.0%) 66 (37.3%) 28 (15.8%) 51 (28.8%) 98 (55.4%) 31 (19.4%) 49 (30.6%) 80 (50.0%) 26 (16.3%) 40 (25.0%) 94 (58.8%)
OR (95% CI) 1.00 1.21 (0.77-
1.88)
1.21 (0.77-
1.88)
1.00 2.03 (1.22-
3.37)
5.43 (3.18-
9.26)
1.00 1.20 (0.73-
1.97)
1.68 (1.03-
2.71)
1.00 1.47 (0.87-
2.49)
3.92 (2.40-
6.38)
Low HDL
cholesterolemia
10 (15.9%) 26 (41.3%) 27 (42.9%) 23 (33.8) 24 (38.1%) 16 (25.4%) 42 (23.7%) 55 (31.1%) 80 (45.2%) 53 (29.9%) 59 (33.3%) 65 (36.7%)
OR (95% CI) 1.00 2.85 (1.33-
6.12)
2.79 (1.28-
6.07)
1.00 0.94 (0.50-
1.76)
0.76 (0.36-
1.64)
1.00 1.29 (0.83-
2.00)
1.95 (1.25-
3.02)
1.00 1.12 (0.74-
1.69)
1.17 (0.77-
1.79)
Impaired fasting glucose 46 (23.8%) 70 (36.3%) 77 (39.9%) 50 (25.9%) 62 (32.1%) 81 (42.0%) 28 (19.3%) 38 (26.2%) 79 (54.5%) 28 (19.3%) 46 (31.7%) 71 (49.0%)
OR (95% CI) 1.00 1.73 (1.12-
2.67)
1.82 (1.17-
2.82)
1.00 1.54 (0.99-
2.40)
2.81 (1.72-
4.59)
1.00 1.12 (0.66-
1.90)
2.24 (1.37-
3.66)
1.00 1.55 (0.93-
2.59)
2.36 (1.44-
3.88)
HOMA-IR ≥2.6† 12 (11.9%) 37 (36.6%) 52 (51.5%) 18 (17.8%) 36 (35.6%) 47 (46.5%) 23 (13.3%) 49 (28.3%) 101 (58.4%) 18 (10.4%) 58 (33.5%) 97 (56.1)
OR (95% CI) 1.00 3.40 (1.08-
3.73)
5.14 (2.60-
10.1)
1.00 2.01 (1.08-
3.73)
3.00 (1.55-
5.82)
1.00 1.78 (1.04-
3.04)
3.51 (2.11-
5.86)
1.00 3.13 (1.78-
5.49)
4.99 (2.89-
8.64)
Study subjects were divided into three groups (tertiles) according to hsCRP and GGT levels within sex. OR, odds ratio; CI, confidence interval.
† Insulin resistance was defined as HOMA-IR ≥2.6. Adjusted for age, smoking status, alcohol consumption, uric acid, and estimated glomerular filtration rate.
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also increased significantly in relation to hsCRP and
GGT in both genders.
Synergistic effect of GGT and hsCRP on mean
accumulating number of MetS components and insulin
resistance
In addiction to their direct associations, we observed a
synergistic effect between hsCRP and GGT (Figure 1).
In Figure 1 subjects were divided into three groups (ter-
tiles) according to CRP and GGT levels within sex. We
assessed the statistical significance of the synergistic
relationship using a general linear model with the fol-
lowing confounding factors: age, smoking status, alcohol
consumption, uric acid, eGFR (Table 4). The interaction
between increased hsCRP and GGT was a significant
and independent determinant for MetS and HOMA-IR
≥2.6 in both genders.
Association between hsCRP and GGT levels, and
metabolic syndrome and HOMA-IR, within selected
subgroups
Next, to control potential confounding by MetS and
insulin resistance, the data were further stratified by age,
alcohol consumption, uric acid, HMW adiponectin, and
medication (e.g., antihypertensive, antilipidemic, and dia-
betic medication) (Table 5). The ORs for MetS and
HOMA-IR ≥2.6 increased significantly in relation to
hsCRP and GGT in almost all the subgroups.
Discussion
In 1,919 community-dwelling subjects, we determined
t h ep r e v a l e n c er a t eo fM e t S ,a sd e f i n e db ym o d i f i e d
NCEP-ATPIII criteria [20], and examined the associa-
tion between hsCRP and GGT, and MetS and its com-
ponents. MetS was common, occurring in 17.2% of men
and 15.5% of women. In both men and women, the
Figure 1 Synergistic effect of GGT and hsCRP.A ,M e a na c c u m u l a t i n gn u m b e ro fm e t a b o l i cs y n d r o m ec o m p o n e n t s :o b e s i t y ,r a i s e db l o o d
pressure, hypertriglyceridemia, low high-density lipoprotein cholesterolemia, and impaired fasting glucose. B, HOMA-IR. Study subjects were
divided into three groups (tertiles) according to GGT and hsCRP levels. Each tertile was calculated within sex and then combined to avoid the
gender differences.
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Page 6 of 10prevalence rate of MetS increased significantly in rela-
tion to hsCRP and GGT, even after adjusting for age,
smoking status, drinking status, uric acid, and eGFR.
The OR of MetS increased dose-dependently with
increasing tertiles of hsCRP and GGT. In addition, we
demonstrated that there is an interaction between
increased hsCRP and GGT. The ORs of MetS and
HOMA-IR ≥2.6 were significantly increased in relation
to hsCRP and GGT in almost all the subgroups strati-
fied by age, alcohol consumption, uric acid, HMW adi-
ponectin, and medication. To our knowledge, this is the
first study to indicate these associations of CRP and
GGT with MetS and insulin resistance in about 2,000
community-dwelling subjects.
Systemic inflammation is closely associated with the
pathogenesis of MetS. Several previous studies have
demonstrated that elevated CRP was associated with
increased odds of MetS after adjusting for potential con-
founding factors [23-26]. In a rural Chinese population,
compared with subjects without components of MetS,
t h o s ew i t h1 ,2 ,3 ,4 ,a n d5c o m p o n e n t so fM e t Sh a d
ORs of 1.39, 1.08, 1.84, 2.65, and 1.21 for elevated CRP
in men and 1.91, 2.06, 3.10, 4.06, and 6.01 in women,
respectively [27].
In our study, higher GGT levels were also positively
associated with MetS, independent of other confoun-
ders. Similar results have been reported in recent studies
[28,29]. Nakanishi et al [28] demonstrated that serum
GGT may be an important predictor for developing
MetS in 2,957 metabolic syndrome-free men and 3,260
nondiabetic men aged 35-59 years. After adjustments
f o ra g e ,f a m i l yh i s t o r yo fd i a b e t e s ,B M I ,a l c o h o li n t a k e ,
smoking status, regular physical activity, and white
blood cell count, increased serum GGT was related to
the risk of developing MetS, even among individuals
with normal GGT concentrations, this is a finding con-
sistent with previous prospective reports looking at
GGT. Among a total 3246 Korean adults, the number of
MetS components, prevalence of MetS, and insulin
resistance (HOMA-IR) increased closely as the quartile
o fs e r u mG G Ti n c r e a s e d[ 3 0 ] .A n d r ée ta la l s od e m o n -
strated that serum GGT is an important predictor for
developing MetS in 1,659 men and 1,889 women with-
out MetS at baseline [31]. Moreover, in a pooled logistic
analysis after adjustments for age, alcohol intake, smok-
ing status, physical activity, alanine aminotransferase,
fasting insulin and HOMA-IR, high baseline GGT con-
centrations predicted future development of MetS
defined by the IDF and AHA/NHLBI criteria after 4 y
of follow-up [32]. In a community-based cohort study of
9,148 Korean adults that included 1056 men, the risk of
MetS occurring increased across the baseline GGT
quartiles, independent of age plus the time elapsed from
visit 1 to visit 2, baseline MetS, uric acid, regular exer-
cise, alcohol consumption, and smoking, and even after
further updating GGT values during the follow-up [33].
We also suggested that higher serum GGT was signifi-
cantly associated with MetS and its components in the
same population and this association was related with
insulin resistance, independent of other confounding
factors [34]. A unique point of this result is that hsCRP
and GGT were independently and synergistically asso-
ciated with MetS, its components and insulin resistance.
The mechanisms by which hsCRP and GGT reflect
the risk for MetS are not completely understood. How-
ever, systemic inflammation is closely involved in the
pathogenesis of MetS, and thus, both elevated hsCRP
and GGT may also reflect inflammation, which impairs
insulin signaling in the liver, muscle, and adipose tissues
[35]. Fat accumulation in the liver or adipose tissues can
induce inflammatory cytokines such as tumor necrosis
factor-a, interleukin-6, and interleukin-8 [36]. These
cytokines produced by adipocytes stimulate the hepatic
synthesis of CRP, which is an acute-phase protein, and
Table 4 Interaction between hsCRP and GGT for metabolic syndrome and insulin resistance
F( P-value)
Characteristics Men, N = 822 Women, N = 1,097
Metabolic syndrome HOMA-IR ≥2.6† Metabolic syndrome HOMA-IR ≥2.6†
Age (years) 0.058 (0.810) 3.774 (0.052) 0.329 (0.566) 0.015 (0.902)
Smoking status, N (%) 2.097 (0.148) 4.359 (0.037) 1.252 (0.263) 3.667 (0.056)
Alcohol consumption, N (%) 6.959 (0.008) 10.29 (0.001) 3.454 (0.063) 0.306 (0.580)
Uric acid (mg/dL) 0.003 (0.954) 1.592 (0.207) 10.07 (0.002) 5.156 (0.023)
eGFR (mL/min/1.73 m
2) 0.679 (0.410) 1.820 (0.178) 1.161 (0.282) 0.172 (0.679)
Tertile of hsCRP 1.165 (0.281) 0.177 (0.674) 0.098 (0.755) 1.394 (0.238)
Tertile of GGT 0.196 (0.658) 0.813 (0.368) 0.440 (0.507) 0.944 (0.331)
Tertile of hsCRP * Tertile of GGT 5.965 (0.015) 6.684 (0.010) 5.898 (0.015) 12.86 (<0.001)
Metabolic syndrome was defined as having three or more of the following conditions: obesity, raised blood pressure, hypertriglyceridemia, low HDL
cholesterolemia, and impaired fasting blood glucose. † Insulin resistance was defined as HOMA-IR ≥2.6. The net effect of each interaction was estimated using a
general linear model.
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Page 7 of 10Table 5 Association between hsCRP and GGT levels, and metabolic syndrome and Insulin resistance, within selected subgroups
Metabolic syndrome OR(95% CI). HOMA-IR ≥2.6† OR(95% CI).
Tertile of hsCRP Tertile of GGT Tertile of hsCRP Tertile of GGT
1st 2nd 3rd 1st 2
nd 3rd 1st 2nd 3rd 1st 2nd 3rd
Characteristics <0.360 0.360-0.800 >0.800 mg/L <29 29-54 >54 IU/L <0.280 0.280-0.650 >0.650 mg/L <18 18-24 >24 IU/L
Age
<65 years 650 1.00 2.13 (1.26-3.59) 3.76 (2.25-6.27) 1.00 2.66 (1.50-4.72) 3.55 (2.00-6.31) 1.00 2.50 (1.44-4.33) 4.50 (2.62-7.72) 1.00 2.47 (1.37-4.45) 3.04 (1.70-5.42)
≥65 years 969 1.00 1.21 (0.73-2.03) 1.88 (1.16-3.06) 1.00 1.84 (1.12-3.04) 3.80 (2.31-6.28) 1.00 2.16 (1.12-4.15) 3.87 (2.08-7.19) 1.00 2.16 (1.12-4.15) 3.87 (2.08-7.19)
Alcohol consumption
Absent 829 1.00 1.42 (0.83-2.44) 2.27 (1.34-3.85) 1.00 1.94 (1.16-3.25) 3.04 (1.78-5.10) 1.00 1.11 (0.62-1.98) 2.23 (1.29-3.87) 1.00 4.72 (2.47-9.03) 7.41 (3.81-14.4)
Present 1090 1.00 1.74 (1.07-2.84) 2.91 (1.82-4.66) 1.00 2.65 (1.54-4.58) 4.89 (2.83-8.44) 1.00 4.50 (2.37-8.54) 7.30 (3.88-13.7) 1.00 1.62 (0.93-2.82) 2.66 (1.55-4.55)
Uric acid
<5.0 (mean) mg/dL 978 1.00 1.51 (0.87-2.60) 3.21 (1.90-5.40) 1.00 2.39 (4.41-4.05) 3.53 (2.07-6.03) 1.00 1.98 (1.11-3.54) 3.57 (2.03-6.29) 1.00 2.79 (1.59-4.89) 3.46 (1.95-6.14)
≥5.0 (mean) mg/dL 941 1.00 1.68 (1.03-2.75) 2.14 (1.33-3.44) 1.00 2.24 (1.32-3.79) 4.04 (2.38-6.85) 1.00 1.68 (1.03-2.75) 2.14 (1.33-3.44) 1.00 2.24 (1.32-3.79) 4.04 (2.38-6.85)
HMW adiponectin
<5.03 (median) μg/mL 963 1.00 1.64 (1.02-2.64) 2.74 (1.73-4.32) 1.00 2.63 (1.63-4.23) 3.52 (2.18-5.69) 1.00 2.63 (1.50-4.60) 4.57 (2.66-7.87) 1.00 1.86 (1.11-3.09) 3.23 (1.97-5.30)
≥5.03 (median) μg/mL 956 1.00 1.27 (0.71-2.27) 1.53 (0.85-2.75) 1.00 1.79 (0.96-3.34) 3.76 (2.04-6.96) 1.00 1.61 (0.84-3.10) 2.12 (1.11-4.05) 1.00 4.41 (2.07-9.42) 5.09 (2.33-11.1)
Medication‡
Absent 1342 1.00 1.76 (1.09-2.85) 3.11 (1.95-4.93) 1.00 2.02 (1.23-3.31) 3.36 (2.06-5.50) 1.00 3.24 (1.87-5.62) 5.73 (3.34-9.84) 1.00 2.39 (1.43-3.97) 3.05 (1.84-5.07)
Present 577 1.00 1.18 (0.66-2.09) 1.87 (1.07-3.25) 1.00 2.22 (1.24-3.96) 3.55 (1.95-6.44) 1.00 1.12 (0.57-2.19) 2.07 (1.10-3.88) 1.00 2.94 (1.43-6.06) 6.09 (2.94-12.6)
Metabolic syndrome was defined as having three or more of the following conditions: obesity, raised blood pressure, hypertriglyceridemia, low HDL cholesterolemia, and impaired fasting blood glucose. † Insulin
resistance was defined as HOMA-IR ≥2.6. ‡Medication was defined as antihypertensive, antilipidemic, or diabetic medication. Each tertile was calculated within sex and then combined to avoid the gender
differences. Values adjusted for sex, age, smoking status, alcohol consumption, uric acid, and estimated glomerular filtration rate.
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0influence insulin resistance, lipid and glucose metabo-
lism. [37]. Moreover, high GGT is strongly associated
with higher CRP levels [38], suggesting that this enzyme
represents the expression of subclinical inflammation,
and has a role in cellular stress [39]. On the other hand,
we have been also reported that increased hsCRP and
decreased high molecular weight (HMW) adiponectin
are synergistically associated with the accumulation of
metabolic disorders [40], however, both hsCRP and
GGT were associated with insulin resistance also in sub-
groups stratified by HMW adiponectin. Furthermore, It
has been demonstrated that increased GGT levels might
be an antioxidant marker (defensive response) to oxida-
tive stress or a direct marker of oxidative stress, which
is involved directly in the generation of reactive oxygen
species (ROS), especially in the presence of iron or
other transition metals, inducing lipid peroxidation in
human biological membranes [41,42].
There are some limitations to this study. First, our
cross-sectional study design does not eliminate potential
causal relationships between CRP, GGT and MetS. Sec-
ond, the prevalence rate of MetS, GGT, and hsCRP
categories is based on a single assessment of blood,
which may introduce a misclassification bias. Third, we
used BMI ≥25 to classify individuals with visceral obe-
sity because waist circumference measurements were
not available, which might have caused an under or over
estimation of the effect of visceral obesity on MetS [43].
In fact, the prevalence rate of MetS in women was
higher than those of the general reports in Japanese
[1,44]. Fourth, serum GGT levels are various for same
alcoholic consumption, and the possible association of
the fatty liver with the presence of MetS, and with the
elevated GGT could not be accurately explored. Thus,
we demonstrated that GTT are independently associated
with MetS after adjustment for alcoholic consumption
a n da l s oi ns u b g r o u po fd r i n k e ra n dn o n - d r i n k e r ,s u g -
gesting drinking status does not dramatically affect the
usefulness of g-GTP as a biomarker for MetS risk. Fifth,
the presence of viral hepatitis must be considered, but
examinations of hepatitis B surface antigen and antibody
to hepatitis C were not performed. In addition, the rate
of taking antilipidemic medication in men with Mets
was a little low; however we cannot explain that back-
ground. Therefore the demographics and referral source
may limit generalizability.
Conclusion
In conclusion, the present study showed that hsCRP and
G G Tl e v e l sa r es t r o n g l ya s s o c i ated with MetS or its compo-
nents in the general population. The underlying mechanism
behind this relationship is unclear, but seems to be inde-
pendent of traditional cardiovascular risk factors such as
age, smoking status, alcohol consumption, uric acid, or
renal function. For community-dwelling healthy persons,
prospective population-based studies are needed to investi-
gate the mechanisms underlying this association to deter-
mine whether intervention, such as effective lifestyle
modifications or medication (e.g., antihypertensive, antilipi-
demic, and diabetic medication) that decrease hsCRP and
GGT in adults [45], will decrease the risk of MetS.
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